VivoSeq
Ophthalmology

Keratitis

31

Pipeline Programs↗

9

Active Trials↗

15

Companies Involved↗

Keratitis is a moderately active landscape with 31 programs across 15 companies. The most active players are IVIEW Therapeutics Inc., Staidson (Beijing) Biopharmaceuticals Co., Ltd, Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.. 11 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

19/100

Mech. Concentration

44/100

Completion Rate

76/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

IVIEW Therapeutics Inc.

2 programs

Phase 2S

Staidson (Beijing) Biopharmaceuticals Co., Ltd

1 program

Phase 2Z

Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

1 program

Phase 2B

BRIM Biotechnology Inc.

1 program

Phase 2R

RECORDATI GROUP

1 program

Phase 2K

Krystal Biotech, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

96%

Small molecule

50 of 52 classified programs — the dominant modality here.

4%ALL OTHERSProtein / enzyme24%

Small molecule leads; the ring shows all 52 classified programs, each share of the total. Modality classified for 100% of 56 pipeline programs.

Analysis

Trial Status

38

clinical trials

Completed16 · 42%
Unknown status8 · 21%
Recruiting5 · 13%
Withdrawn3 · 8%
Not yet recruiting3 · 8%
Terminated2 · 5%
Other1 · 3%

Clinical Trials

Trial Activity

38 trials

Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
Recruiting·EEye & ENT Hospital of Fudan University·Phase 1·NCT06451172·20 enrolled
Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis
Recruiting·MMinia University·N/A·NCT07394257·60 enrolled
A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis
Recruiting·SStaidson (Beijing) Biopharmaceuticals Co., Ltd·Phase 2·NCT06975748·48 enrolled
Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
Recruiting·BBRIM Biotechnology Inc.·Phase 2·NCT05927428·12 enrolled
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
Recruiting·KKrystal Biotech, Inc.·Phase 1/2·NCT06999733·60 enrolled
DOMPE -MT Neurotrophic Keratitis
Active, not recruiting·TToyos Clinic·Phase 4·NCT06947850·10 enrolled
Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis
Not yet recruiting·IIVIEW Therapeutics Inc.·Phase 2·NCT06463678·60 enrolled
Effect of Sodium Chloride 5% Solution as an Adjuvant Treatment With Antimicrobial Therapy in the Treatment of Bacterial Infectious Keratitis
Not yet recruiting·SSohag University·N/A·NCT07452588·40 enrolled
Corneal Neurotization vs. Cenergermin for Neurotrophic Keratitis: A Pilot Study
Not yet recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·N/A·NCT07073729·10 enrolled
The Role of Adjuvant Corneal Crosslinking in the Management of Infective Keratitis
Completed·RResearch Institute of Ophthalmology, Egypt·Phase 1·NCT06967376·40 enrolled
The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study
Completed·—·N/A·NCT05655689·123 enrolled
To Evaluate the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects Caused by Neurotrophic Keratitis
Completed·ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.·Phase 2·NCT07120308·28 enrolled
Wharton's Jelly Eye Drops in the Treatment of Chronic Keratitis
Completed·TTBF Genie Tissulaire·Phase 1·NCT05200000·20 enrolled
Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis
Completed·—·Phase 4·NCT04485546·37 enrolled
Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis
Completed·—·N/A·NCT06757907·20 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)